Recent Updates
Recently added Catalysts
ATHE

APPENDIX 3B Exhibit 1 Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New Issue Announcement, Application for Quotation of Additional Securities and Agreement Information or documents not available now must be given to ASX

Key Takeaway: 2.7, 3.10.3, 3.10.4, 3.10.5 New Issue Announcement, Application for Quotation of Additional Securities and Agreement or documents not available now must be given to ASX as soon as available. and documents given to ASX become ASX's property and may be made public. 01/07/96 O

Full Press Release Details

2.7, 3.10.3, 3.10.4, 3.10.5
New Issue Announcement,
Application for Quotation of Additional
Securities and Agreement
or documents not available now must be given to ASX as soon as available.
and documents given to ASX become ASX's property and may be made public.
01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13
Name of Entity
Alterity Therapeutics Limited (ASX: ATH)
ABN
37 080 699 065
entity) give ASX the following information.
must complete the relevant sections (attach sheets if there is not enough space).
1 +Class of +securities issued or to be issued Ordinary Shares (ATH)
2 Number of +securities issued or to be issued (if known) or maximum number which may be issued 7,962,060
3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) Fully paid ordinary shares (ATH)
4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Yes
5 Issue price or consideration USD 191,912
6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) To fund the Company's current clinical development, research programs and working capital. This is an on-going placement - more tranches will be allotted in the future.
6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B , and comply with section 6i Yes
6b The date the security holder resolution under rule 7.1A was passed 16 November 2018
6c Number of +securities issued without security holder approval under rule 7.1 7,962,060
6d Number of +securities issued with security holder approval under rule 7.1A Nil
6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) Nil
6f Number of +securities issued under an exception in rule 7.2 Nil
6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. N/A
6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements N/A
6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements Refer to the attached Annexure 1
Number + Class
8 Number and +class of all +securities quoted on ASX ( including the +securities in section 2 if applicable) 868,799,492 Fully Paid Ordinary Shares (ATH)
9 Number and + class of all + securities not quoted on ASX ( including the + securities in section 2 if applicable)
Class of Securities Issued
ASX Code Number Security Type Exercise Price Expiry Date under an ESOP
PBTAH 2,000,000 Unlisted Options AUD$0.26 18 Feb 2020 2004 ASX Plan
PBTAR 1,400,000 Unlisted Options AUD$0.27 25 May 2020 2004 ASX Plan
PBTAS 7,350,000 Unlisted Options AUD$0.07 6 Jun 2022 2004 ASX Plan
PBTAAA 13,850,000 Unlisted Options AUD$0.11 14 Dec 2022 2004 ASX Plan
PBTAI 700,000 Unlisted Options AUD $0.083 31 January 2023 2004 ASX Plan
NEW CLASS 586,672,964 Short-term warrants AUD $0.045 19 December 2019 No
TOTAL 611,972,964
Part 2 - Pro rata issue - n/a
11 Is security holder approval required?
12 Is the issue renounceable or non-renounceable?
13 Ratio in which the + securities will be offered
14 + Class of + securities to which the offer relates
15 + Record date to determine entitlements
16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17 Policy for deciding entitlements in relation to fractions
18 Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.
19 Closing date for receipt of acceptances or renunciations
20 Names of any underwriters
21 Amount of any underwriting fee or commission
22 Names of any brokers to the issue
23 Fee or commission payable to the broker to the issue
24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
25 If the issue is contingent on security holders' approval, the date of the meeting
26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28 Date rights trading will begin (if applicable)
29 Date rights trading will end (if applicable)
30 How do security holders sell their entitlements in full through a broker?
31 How do security holders sell part of their entitlements through a broker and accept for the balance?
32 How do security holders dispose of their entitlements (except by sale through a broker)?
33 + Issue date
Part 3 - Quotation of securities
need only complete this section if you are applying for quotation of securities
34 Type of + securities ( tick one )
(a) + Securities described in Part 1
(b) All other + securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)
Additional securities forming a new
class of securities - n/a
35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37 A copy of any trust deed for the additional +securities
Entities that have ticked box 34(b)
38 Number of + securities for which + quotation is sought
39 + Class of + securities for which quotation is sought
40 Do the + securities rank equally in all respects from the + issue date with an existing + class of quoted + securities? If the additional + securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another + security, clearly identify that other + security)
Number + Class
42 Number and + class of all + securities quoted on ASX ( including the + securities in clause 38)
may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
/s/ Phillip Hains Date: Thursday, 1 st August 2019
Sign here: Company Secretary
Print name: Phillip Hains
Calculation of placement capacity under
rule 7.1 and rule 7.1A for eligible entities
01/08/12 Amended 04/03/13
Rule 7.1 - Issues exceeding 15% of capital
Step 1: Calculate "A", the base figure from which the placement capacity is calculated
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue 536,975,050
Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here - other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Nil 311,038,282 Nil
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period Nil
"A" 848,013,332
Step 2: Calculate 15% of "A"
"B" 0.15 [Note: this value cannot be changed]
Multiply "A" by 0.15 127,202,000
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded - not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 20,786,160
"C" 20,786,160
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1
"A" x 0.15 Note: number must be same as shown in Step 2 127,202,000
Subtract "C" Note: number must be same as shown in Step 3 20,786,160
Total ["A" x 0.15] - "C" 106,415,840 [ Note : this is the remaining placement capacity under rule 7.1]
Rule 7.1A - Additional placement capacity for eligible entities
Step 1: Calculate "A", the base figure from which the placement capacity is calculated
Step 2: Calculate 10% of "A"
"D" 0.10 Note: this value cannot be changed
Multiply "A" by 0.10 84,801,333
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities - not just ordinary securities Include here - if applicable - the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items Nil
"E" Nil
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A
" A " x 0.10 Note: number must be same as shown in Step 2 84,801,333
Subtract "E" Note: number must be same as shown in Step 3 Nil
Total ["A" x 0.10] - "E" 84,801,333 Note: This is the remaining placement capacity under rule 7.1A
Under Section 708A(5) of the Corporations Act
notice is given under paragraph (5)(e) of section 708A of the Corporations Act.
Type: Shares
Class/Description: Ordinary Fully Paid
ASX Code: ATH
Date of Issue: Wednesday, 31 st July 2019
Number Issued: 7,962,060
Issue Consideration: USD 191,912
Company intends to apply to Australian Stock Exchange Limited for quotation of the above shares.
Accordingly, the Company
gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the "Corporations Act") that:
and on behalf of the Company,
/s/ Phillip Hains
Phillip Hains Company Secretary Alterity Therapeutics Limited
Last updated: Aug 1, 2019